Aclarion Expands CLARITY Trial to Private Practice with Beverly Hills Spine Clinic
Event summary
- Aclarion adds Lanman Spinal Neurosurgery as first private practice site in CLARITY trial, expanding beyond academic medical centers.
- CLARITY trial aims to enroll 300 patients, with initial interim results expected in Q4 2026.
- Nociscan platform claims 97% surgical success rate when all positive discs are treated.
- Trial primary endpoint: 12-month change in back pain measured on 100mm VAS scale.
The big picture
Aclarion's expansion into private practice settings marks a strategic shift from academic centers, targeting the majority of chronic low back pain treatments. The move reflects growing demand for data-driven diagnostic tools in real-world clinical workflows. With 266 million people globally suffering from degenerative spine disease, Nociscan's ability to non-invasively identify pain-generating discs positions it at the forefront of precision spine care.
What we're watching
- Trial Execution
- Whether Aclarion can maintain enrollment momentum through private practice sites after academic center expansion.
- Regulatory Pathway
- How Q4 2026 interim results may influence Nociscan's commercial adoption and reimbursement discussions.
- Market Differentiation
- The pace at which Nociscan can establish clinical superiority over standard MRI diagnostics in chronic low back pain.
Related topics